Clinical Trials · NCT04017832
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,441
- Start date
- Jul 2019
- Locations
- 93 sites, 9 countries
- Primary endpoint
- Change From Baseline to Week 26 in Glycated Haemoglobin (HbA1c) (%)